深圳未名新鹏生物医药

Shenzhen Sinobioway Xinpeng Biomedicine is a Chinese biopharmaceutical company established in 1992 and based in Shenzhen. Originally founded as Shenzhen Xinpeng Biological Engineering, the company is a subsidiary of the Sinobioway Group and is one of the earliest enterprises in China to engage in biopharmaceutical research and industrialization. The company specializes in the development, manufacturing, and commercialization of recombinant protein therapeutics, with a focus on hematology and oncology. Its commercial portfolio includes recombinant human granulocyte colony-stimulating factor (G-CSF) injection for neutropenia and recombinant human erythropoietin (EPO) injection for renal and cancer-related anemia. Additionally, the company's pipeline features long-acting PEGylated G-CSF and recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) for cancer therapy.